Lexatumumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Lexatumumab
Monoclonal antibody
Type Whole antibody
Source Human
Target TRAIL-R2
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6346H9832N1720O2002S42
Molar mass 143.6 kg/mol
 NYesY (what is this?)  (verify)

Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2) undergoing clinical trials for the treatment of cancer.[1]

HGS-ETR2 antibodies were generated by HGS through a collaboration with Cambridge Antibody Technology.[2]

References[edit]

  1. ^ Statement on a Nonproprietary Name adopted by the USAN Council - Lexatumumab, American Medical Association.
  2. ^ http://www.hgsi.com/trail-receptor-antibodies-5.html